Recombinant turkey herpesvirus HVT-H9-IBD expressing two exogenous genes and application thereof
The problems of existing vaccine immune competition and flock stress were solved by inserting the recombinant virus HVT-H9-IBD of the H9N2 AIV HA gene and nVarIBDV VP2 gene in the turkey herpes virus, and simultaneous immunity to H9N2 AIV and nVarIBDV were achieved. Protection reduces breeding costs and immune fatigue, and provides effective protection against the current epidemic strains.
Patent Information
- Application Number
- CN202410395561.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-04-02
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2044-04-02
AI Technical Summary
The existing inactivated vaccines have immune competition in preventing and controlling H9N2 AIV and nVarIBDV, which cannot induce good immune protection, and multiple immunizations have caused stress and immune fatigue in the chickens. The infectious bursal disease has caused a huge economic impact on the poultry industry. loss.
The recombinant turkey herpes virus HVT-H9-IBD expressing the H9N2 AIV HA gene and nVarIBDV VP2 gene was constructed to ensure that the virus can replicate stably and provide good immune protection by inserting the target gene at a specific site of the turkey herpes virus.
Simultaneous immune protection against H9N2 AIV and nVarIBDV is achieved, reducing flock stress, improving immune durability, reducing the workload of breeders, and providing effective protection against the current epidemic strains.
Smart Images

Figure CN118879643A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the field of biotechnology, in particular to a recombinant turkey herpes virus HVT-H9-IBD expressing two exogenous genes and an application thereof. Background Art
[0002] The H9N2 subtype AIV is prevalent worldwide and can infect a variety of poultry species, including chickens, ducks, turkeys, quails, wild ducks, seabirds, etc. (Xu et al. J Virol, 2007). Therefore, strengthening the prevention and control of H9N2 AIV and reducing the spread and prevalence of the virus are of great practical significance to the poultry farming industry and human public health safety.
[0003] At present, inactivated vaccines are mainly used to prevent and control H9 subtype AIV. However, inactivated vaccines can only produce humoral immunity and cannot effectively control viral infection and detoxification. Egg-laying hens or breeder flocks with long breeding cycles need multiple injections to improve antibody levels. However, this immunization method brings a huge workload to the breeders, and each immunization will cause stress to the chickens, reducing production efficiency. At the same time, the adjuvant components in the inactivated vaccine are prone to cause allergies or muscle necrosis at the injection site, reducing production quality. In addition, excessive immunization will cause immune fatigue in the body and reduce the immune effect of various vaccines.
[0004] Infectious bursal disease (IBD) is one of the most important immunosuppressive poultry infectious diseases in poultry, causing huge economic losses to the poultry industry worldwide. The atypical IBD caused by nVarIBDV does not cause obvious external symptoms or death, but the central immune organ bursa of Fabricius is severely damaged, resulting in severe immunosuppression and decreased production performance in infected chickens. It causes severe immunosuppression in chickens, bringing new threats to the poultry industry.
[0005] Vaccine immunization is an effective means to prevent and control IBDV infection. Epidemiological survey results show that H9N2 AIV and nVarIBDV often occur concurrently or secondary, causing huge economic losses to the breeding industry. However, when chickens are immunized with HVT-H9 and HVT-IBD at the same time, the two exist and compete with each other, resulting in neither of them being able to induce good immune protection. Therefore, it is urgent to develop HVT-H9-IBD. The virus uses HVT virus as a vector, inserts the HA gene of H9N2 AIV virus and the eukaryotic expression cassette of nVarIBDV virus VP2 gene, and can simultaneously express HA protein and VP2 protein, thereby generating protection against H9N2 AIV and nVarIBDV. The constructed recombinant virus can be used as a candidate strain for a triple vaccine for the prevention and control of H9N2 AIV, nVarIBDV and MDV at the same time. HVT-H9-IBD live vector vaccine can effectively avoid the interference of maternal antibodies; after immunizing the chickens, it can simultaneously induce cellular immunity and humoral immunity; one immunization can produce lasting immunity, reduce the stress of multiple immunizations on the chickens, and reduce the workload of breeders, and has broad application prospects.
[0006] CN117551699A discloses a method for constructing a recombinant turkey herpes virus rHVT-HA-VP2, which inserts an expression cassette of the HA gene of the H9 subtype avian influenza virus, an expression cassette of the VP2 gene of the chicken infectious bursal disease virus, and a spacer sequence into the turkey herpes virus genome;
[0007] The specific insertion sites are: between HVT053 and HVT054 on the genome of turkey herpesvirus FC-126, and within the HVT088 gene on the genome of turkey herpesvirus FC-126.
[0008] When this project intended to insert genes at other locations or non-coding regions, it was found that there were problems such as difficulty in insertion and low gene expression titer. This shows that the different insertion sites of the HVT vector platform are very selective for the target gene. Summary of the invention
[0009] The object of the present invention is to provide a recombinant turkey herpes virus HVT-H9-IBD expressing two exogenous genes; the recombinant turkey herpes virus HVT-H9-IBD can grow, replicate and stably inherit in vitro, and provide good immune protection effect against H9N2 subtype avian influenza and nVarIBDV.
[0010] Meanwhile, the invention also provides the use and vaccine of the recombinant turkey herpes virus HVT-H9-IBD.
[0011] To achieve the above object, the present invention provides the following technical solutions:
[0012] A recombinant turkey herpesvirus HVT-H9-IBD expressing two exogenous genes, wherein target gene 1 and target gene 2 are inserted between HVT053 site and HVT054 site (95322-95323) and between HVT065 site and HVT066 site (112072-112073) of the UL region of turkey herpesvirus, respectively;
[0013] or, inserting target gene 1 and target gene 2 between HVT053 site and HVT054 site and between HVT087 site and HVT088 site (140055-140056) of UL region of turkey herpes virus, respectively;
[0014] The target gene 1 is the HA gene with a CMV promoter and a bgH terminator, and the target gene 2 is the VP2 gene with an mCMV promoter and an SV40 terminator, and recombinant virus 1 and recombinant virus 2 are obtained respectively.
[0015] In the above-mentioned recombinant turkey herpes virus HVT-H9-IBD, the nucleotide sequence of the HA gene is shown in SEQ ID NO.1; the nucleotide sequence of the VP2 gene is shown in SEQ ID NO.2.
[0016] In the above-mentioned recombinant turkey herpes virus HVT-H9-IBD, the promoter of the inserted HA gene is the CMV promoter, and the terminator is the bgH terminator; the promoter of the inserted VP2 gene is the mCMV promoter, and the terminator is the SV40 terminator.
[0017] The nucleotide sequence of the target gene 1 with a promoter and a terminator is shown in SEQ ID NO.3; the nucleotide sequence of the target gene 2 with a promoter and a terminator is shown in SEQ ID NO.4;
[0018] At the same time, the present invention also discloses the use of the recombinant turkey herpes virus HVT-H9-IBD as described above to prepare a vaccine for preventing infection by H9N2 subtype avian influenza and new variants of infectious bursal disease.
[0019] Finally, the present invention also discloses a vaccine containing any of the above-mentioned recombinant turkey herpes virus HVT-H9-IBD.
[0020] Compared with the prior art, the present invention has the following beneficial effects:
[0021] 1. The hypervariable region of the VP2 gene of the present invention has 12 amino acid mutations, and its antigenicity has mutated. By inserting the VP2 gene expression cassette into the turkey herpes virus, it is verified that the recombinant turkey herpes virus HVT-H9-IBD has extremely strong protective power;
[0022] Compared with the VP2 genes of other IBDVs isolated in the same period, the VP2 gene selected by the present invention is easier to insert into the HVT087 site and the HVT065 site of the UL region; at the same time, the VP2 gene selected by the present invention has a better immune protection effect after expression.
[0023] At the same time, the present invention also evaluated the insertion effect of HVT087 and HVT065 sites, and concluded that the immune protection effect of HVT087 site is better;
[0024] At the same time, the insertion of the HVT065 site will affect the expression immune protection effect of the inserted HA gene, which shows that the HVT087 site and the specific VP2 gene selected by the present invention have very strong synergy.
[0025] 2. In recent years, the antigenicity of H9N2 subtype avian influenza virus has continued to mutate. The HA protein antigenic epitope is mainly located in the head of the trimer HA protein. The mutation of the key amino acid site of the HA protein head changes the antigenicity of the virus, causing the virus to escape from the previous vaccine immunity. Previous studies have divided the representative H9N2 strains from 1994 to 2008 into 5 antigenic groups, from group A to group E. The distribution of antigenic groups is significantly correlated with the year of isolation, indicating that H9N2 AIV is undergoing continuous antigenic changes. However, the update of vaccine strains is slow, lagging behind the changes in antigenic groups. Recent research results show that China's H9N2 has evolved into two antigenic groups, with a difference in HI cross titer between 8 and 32 times, and a large difference in antigenicity, which can be called antigenic groups F and G. Among them, the G antigenic group further mutated and differentiated into G1, G2, and G3 antigenic groups. According to previous studies in this laboratory, the current G3 antigenic group is the most prevalent H9N2 subtype avian influenza virus subgroup in China, and the inserted sequence should provide good protection against the current prevalent strains.
[0026] The HA gene of the present invention is a typical G3 antigen group H9N2 subtype avian influenza virus, which belongs to the antigen subgroup currently popular on the market. By transferring the HA gene into the turkey herpes virus, it is verified that it has extremely strong protective power;
[0027] 3. The present invention utilizes the infectious clone HVT-BAC constructed in the previous patent to construct a strain expressing the HA protein against the H9N2 subtype avian influenza virus and the VP2 protein of nVarIBDV. Its replication ability is consistent with that of the parent virus, and it can provide good immune protection for the H9N2 subtype avian influenza virus and the new variant of IBDV, meeting the requirements of vaccine candidate strains;
[0028] 4. Based on the constructed infectious clone HVT-BAC, the HA gene insertion site was confirmed to be the HVT053 site. By comparing the inserted VP2 genes at the HVT065 and HVT087 sites, it can be confirmed that the HA and VP2 of the present invention are specific for the selection of the insertion site of the infectious clone HVT-BAC. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] Figure 1 The HA gene evolution tree of the H9N2 subtype avian influenza virus of the embodiment of the present invention; Figure 1A for Figure 1 An enlarged view of a part A; Figure 1B for Figure 1 An enlarged view of part B; Figure 1C for Figure 1 An enlarged view of a local C; Figure 1D for Figure 1 An enlarged view of a local D; Figure 1E for Figure 1 An enlarged view of the local E; Figure 1F for Figure 1 A magnified view of a local F; Figure 1G for Figure 1 A magnified view of a local G; Figure 1H for Figure 1 A magnified view of a local H; Fig. 1I for Figure 1 An enlarged view of a local part I; Figure 1J for Figure 1 An enlarged view of a local J;
[0030] Figure 2A The results of comparing the amino acid site sequences of the HA protein of the A / chicken / chongqing / 120101 / 2022 (CQ / 22) strain of the present invention with the previous H9N2 subtype avian influenza virus strain;
[0031] Figure 2B The comparison results of the key amino acid site sequences of the HA protein of the A / chicken / chongqing / 120101 / 2022 (CQ / 22) strain of the present invention and the previous H9N2 subtype avian influenza virus strain;
[0032] Figure 3 is the IBDV VP2 gene evolution tree of the embodiment of the present invention;
[0033] Figure 4A The comparison results of the gene sequence homology between the three nVarIBDV strains of the present invention and the classical strain BC6 / 85;
[0034] Figure 4B The comparison results of the amino acid sequences of the three nVarIBDV strains of the present invention and the classical strains BC6 / 85 and VP2;
[0035] Figure 5A This is a picture of the bursa of Fabricius autopsy in the IBDV-infected SPF chicken challenge model according to an embodiment of the present invention;
[0036] Figure 5B It is a result diagram comparing the bursal index (BBIX) of SPF chickens infected with IBDV according to an embodiment of the present invention;
[0037] Fig. 6A A schematic diagram of constructing HVT-BAC-H9-065IBD using the galk screening technology of an embodiment of the present invention;
[0038] Figure 6B A schematic diagram of constructing HVT-BAC-H9-087IBD using the galk screening technology of an embodiment of the present invention;
[0039] Fig. 7A This is a schematic diagram of CRISPR / Cas9 deleting the BAC sequence in HVT-BAC-H9-065IBD according to an embodiment of the present invention;
[0040] Figure 7B This is a schematic diagram of CRISPR / Cas9 deleting the BAC sequence in HVT-BAC-H9-087IBD according to an embodiment of the present invention;
[0041] Figure 8 Observation of plaque morphology of recombinant turkey herpesvirus expressing H9N2 subtype avian influenza HA gene and infectious bursal disease novel variant VP2 gene according to the embodiments of the present invention;
[0042] Fig. 9 This is the in vitro growth curve of the recombinant HVT-H9-IBD virus of an embodiment of the present invention;
[0043] Fig.10 The IFA results of the protein expression of the HVT-H9-IBD virus HA gene and VP2 gene of the embodiments of the present invention;
[0044] Fig.11A This is a graph showing the electrophoresis results of HA protein identification 72 hours after HVT-H9-065IBD cells were inoculated in an embodiment of the present invention;
[0045] Fig. 11B This is a graph showing the electrophoresis identification result of VP2 protein 72 hours after HVT-H9-065IBD cells were inoculated in an embodiment of the present invention;
[0046] Fig. 11C This is a graph showing the electrophoresis results of HA protein identification 72 hours after HVT-H9-087IBD cells were inoculated in an embodiment of the present invention;
[0047] Fig.11D This is a graph showing the electrophoresis identification result of VP2 protein 72 hours after HVT-H9-087IBD cells were inoculated in the embodiment of the present invention;
[0048] Fig. 12A This is a PCR test result diagram of the genetic stability of the HA gene in the HVT-H9-065IBD virus cell passage of an embodiment of the present invention, wherein the meanings of the codes are: M is maker; PC is HVT-H9-065IBD virus DNA; P5, P10, P15, and P20 are progeny virus DNAs of HVT-H9-065IBD passaged 5, 10, 15, and 20 generations on CEF cells, respectively; NC is HVT virus DNA;
[0049] Fig. 12B This is a graph showing the genetic stability PCR test results of the VP2 gene in the HVT-H9-065IBD virus cell passage of an embodiment of the present invention, wherein the meanings of the codes are: M is maker; PC is HVT-H9-065IBD virus DNA; P5, P10, P15, and P20 are progeny virus DNAs of HVT-H9-065IBD passaged 5, 10, 15, and 20 generations on CEF cells, respectively; NC is HVT virus DNA;
[0050] Fig. 12C This is a PCR test result diagram of the genetic stability of the HA gene in the HVT-H9-087IBD virus cell passage of an embodiment of the present invention, wherein the meanings of the codes are: M is maker; PC is HVT-H9-087IBD virus DNA; P5, P10, P15, and P20 are progeny virus DNAs of HVT-H9-087IBD passaged 5, 10, 15, and 20 generations on CEF cells, respectively; NC is HVT virus DNA;
[0051] Fig.12DThis is a graph showing the genetic stability PCR test results of the VP2 gene in the HVT-H9-087IBD virus cell passage of an embodiment of the present invention, wherein the meanings of the codes are: M is maker; PC is HVT-H9-087IBD virus DNA; P5, P10, P15, and P20 are progeny virus DNAs of HVT-H9-087IBD passaged 5, 10, 15, and 20 generations on CEF cells, respectively; NC is HVT virus DNA;
[0052] Fig.13A This is a graph showing the results of the detection of HA protein of the HVT-H9-065IBD virus cell passage virus in an embodiment of the present invention, the HVT lane is a negative control; the CQ / 22 lane is a positive control; P5, P10, P15, and P20 represent cell lysates after the virus was passaged for 5, 10, 15, and 20 generations and infected CEF, respectively;
[0053] Fig. 13B This is a graph showing the results of the detection of the VP2 protein of the HVT-H9-065IBD virus cell passage virus of an embodiment of the present invention, wherein the HVT lane is a negative control; the WD / 22 lane is a positive control; P5, P10, P15, and P20 represent cell lysates after the virus was passaged for 5, 10, 15, and 20 generations and infected CEF, respectively;
[0054] Fig. 13C This is a graph showing the results of the detection of HA protein of the HVT-H9-087BD virus cell passage virus of an embodiment of the present invention, the HVT lane is a negative control; the CQ / 22 lane is a positive control; P5, P10, P15, and P20 represent cell lysates after the virus was passaged for 5, 10, 15, and 20 generations and infected CEF, respectively;
[0055] Fig.13D This is a graph showing the results of the detection of the VP2 protein of the HVT-H9-087IBD virus cell passage virus of an embodiment of the present invention, the HVT lane is a negative control; the WD / 22 lane is a positive control; P5, P10, P15, and P20 represent the cell lysates after the virus was passaged for 5, 10, 15, and 20 generations and infected CEF, respectively;
[0056] Fig.14 The HI antibody levels induced by serum immunization on days 14, 21, 28, and 35 after immunization with HVT-H9, HVT-H9-065IBD, HVT-H9-087IBD, and HVT of the embodiments of the present invention;
[0057] Fig.15 This is a result diagram comparing the protection rates of HVT-H9, HVT-H9-065IBD, HVT-H9-087IBD, and HVT after immunization with H9N2 subtype avian influenza in the embodiments of the present invention;
[0058] Fig.16A The bursal index graph of infectious bursal disease homologous virus WD / 22 challenged after HVT-065IBD, HVT-087IBD, HVT-H9-065IBD, HVT-H9-087IBD, and HVT immunization according to the embodiments of the present invention;
[0059] Fig. 16B This is a graph showing the comparative results of the protection rates of HVT-065IBD, HVT-087IBD, HVT-H9-065IBD, HVT-H9-087IBD, and HVT challenged with infectious bursal disease homologous virus WD / 22 after immunization in the embodiments of the present invention;
[0060] Fig.17A The bursal index graph of the virulent BC6 / 85 strain for infectious bursal disease testing after HVT-H9-087IBD, HVT-H9-087IBD / HB, HVT-H9-087IBD / XT, and HVT immunization in the embodiments of the present invention;
[0061] Fig. 17B This is a graph comparing the protection rates of the highly virulent BC6 / 85 strain used for infectious bursal disease testing after HVT-H9-087IBD, HVT-H9-087IBD / HB, HVT-H9-087IBD / XT, and HVT immunization in the embodiments of the present invention. DETAILED DESCRIPTION
[0062] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0063] Reagents and consumables
[0064] Commercial purchase: see Table 1;
[0065] Self-prepared reagents:
[0066] 0.2mg / mL biotin: Dissolve 10mg of biotin in 50mL of ddH2O. After it is completely dissolved, filter it with a 0.22μm filter membrane for sterilization and store it at 4℃ for later use.
[0067] 10 mg / mL L-leucine: Weigh 500 mg of L-leucine and dissolve it in 50 mL of ddH2O. After it is completely dissolved, filter it through a 0.22 μm filter membrane to sterilize it and store it at 4°C until use.
[0068] 1M / L MgSO4: Weigh 12.3 g MgSO4·7H2O and dissolve it in 50 mL ddH2O. After it is completely dissolved, filter it with a 0.22 μm filter membrane to sterilize it and store it at 4°C for later use.
[0069] 20% galactose: Weigh 20 g of galactose and dissolve it in 100 mL of ddH2O. After it is completely dissolved, sterilize it by high pressure and store it at 4°C for later use.
[0070] 20% 2-deoxy-galactose (DOG): Weigh 20 g of DOG and dissolve it in 100 mL of ddH2O. After it is completely dissolved, sterilize it by high pressure and store it at 4°C for later use.
[0071] M9 saline: Weigh 15.13 g Na2HPO4·12H2O, 3 g KH2PO4, 1 g NH4Cl and 0.5 g NaCl and dissolve them in 800 mL ddH2O. Stir thoroughly until dissolved and add ddH2O to make the solution up to 1 L. After high pressure sterilization, store at 4°C for later use.
[0072] 5×M63 culture medium: Weigh 10 g (NH4)2SO4, 68 g KH2PO4 and 2.5 mg FeSO4·7H2O, dissolve in 800 mL ddH2O, stir thoroughly to dissolve, adjust to pH = 7.0 with KOH, make up to 1 L, and sterilize by high pressure.
[0073] Galactose screening culture plate: Weigh 15g agar and dissolve it in 800mL ddH2O. After it is completely dissolved, autoclave at 121℃ for 20min. After taking it out, add 200mL autoclaved 5×M63 culture medium and 1mL MgSO4·7H2O, and adjust the volume to 1L with sterile ddH2O. When the temperature drops to about 50℃, add 5mL 0.2mg / mL biotin, 4.5mL 10mg / mL L-leucine, 10mL 20% galactose and 500μL 50mg / mL chloramphenicol. After fully mixing, pour the plate.
[0074] DOG culture plate: Weigh 15g agar and dissolve it in 800mL ddH2O. After it is completely dissolved, sterilize it at 121℃ for 20min. After taking it out, add 200mL of autoclaved 5×M63 culture medium and 1mL MgSO4·7H2O, and adjust the volume to 1L with sterile ddH2O. When the temperature drops to about 50℃, add 5mL 0.2mg / mL biotin, 4.5mL 10mg / mL L-leucine, 4.5mL 10mg / mL L-isoleucine, 4.5mL 10mg / mL L-valine, 10mL 20% DOG, 10mL20% glycerol and 500μL 50mg / mL chloramphenicol. After fully mixing, pour it onto the plate.
[0075] MacConkey plates containing galactose: Dissolve 40 g of MacConkey medium in 1 L of ddH2O, boil for 1 min, add 10 mL of 20% galactose, autoclave at 121°C for 20 min, and when the temperature drops to about 50°C, add chloramphenicol to a final concentration of 30 μg / mL and pour onto the plates.
[0076] Washing solution: Take 2000mL PBS solution, add 1mL Tween-20, mix well and store at room temperature.
[0077] Blocking solution: Dissolve 5 g skim milk powder in 100 mL washing solution.
[0078] Stop solution: Measure 30 mL of concentrated sulfuric acid and add it to 240 mL of distilled water to prepare 2 mol / L dilute sulfuric acid.
[0079] Items preserved in the laboratory: Fiber2 coated antigen, LMH cells, HVT-BAC infectious clone, SW102 strain, pDC315 vector, pcDNA3.1+ vector, peGFP-galK plasmid are preserved in the laboratory.
[0080] Experimental animals: SPF chickens and chicken embryos were purchased from Beijing Boehringer Ingelheim Weitong Biotechnology Co., Ltd.
[0081] Table 1 Reagents or consumables
[0082]
[0083]
[0084] Table 2 Sequence information
[0085]
[0086]
[0087]
[0088] All primers were synthesized by Beijing Qingke Biotechnology Co., Ltd.
[0089] Part I Isolation of H9N2 subtype avian influenza virus and analysis of HA gene homology
[0090] 1.1 Isolation of H9N2 subtype avian influenza virus
[0091] In 2022, a strain of H9N2 subtype avian influenza virus was isolated from samples collected in Chongqing. The viral RNA was extracted, reverse transcribed, and amplified using the HA open reading frame primer H9-F / R (Table 1) to obtain the H9 gene sequence. The genetic evolution analysis of the HA gene of the isolated H9N2 subtype avian influenza virus showed that ( Figure 1 ), the isolated H9N2 subtype avian influenza virus belongs to the currently prevalent G3 antigen group and was named A / chicken / chongqing / 120101 / 2022 (CQ / 22) strain.
[0092] 1.2 Analysis of amino acid homology of HA proteins of different strains
[0093] Amino acid homology analysis revealed that the isolated CQ / 22 strain gene sequence had undergone significant changes in antigenicity compared with the previously prevalent H9N2 subtype avian influenza virus HA protein ( Figure 2A , Figure 2B ), especially the differences in key amino acid homology may lead to significant changes in antigenicity.
[0094] 1.3 Preparation of CQ / 22 strain virus
[0095] The A / chicken / chongqing / 120101 / 2022 (CQ / 22) strain was selected as a candidate strain for further study. The isolated CQ / 22 virus was inoculated into 9-11 day old SPF chicken embryos to amplify the virus, and the allantoic fluid was collected as seed virus.
[0096] Part II Isolation of nVarIBDV and comparison of VP2 gene homology
[0097] 2.1 Isolation of nVarIBDV
[0098] Three IBDV strains were isolated from samples collected from Shandong, Hebei and other places from 2020 to 2022. Viral RNA was extracted, reverse transcribed, and amplified using the VP2 open reading frame primer VP2-F / R (Table 1) to obtain the VP2 gene sequence. Genetic evolution analysis of the VP2 gene of the isolated IBDV strains showed that the three isolated IBDV strains were all nVarIBDV, named HB / 1208 / 2020, XT / 1203 / 2021 and WD / 0106 / 2022 ( Figure 3 ).
[0099] 2.2 Analysis of VP2 gene homology of different strains
[0100] Homology analysis revealed that the gene sequences of the three isolated nVarIBDV strains had changed significantly from the classic strain BC6 / 85 ( Figure 4A), and 12 amino acid mutations occurred in the VP2 hypervariable region ( Figure 4B ), the antigenicity may have changed significantly.
[0101] 2.3 Establishment of nVarIBDV animal infection model and preparation of seed virus
[0102] The three strains of nVarIBDV were inoculated into chicken embryos to propagate the virus, but the three strains had poor replication ability in chicken embryos, and no virus could be obtained after passage. Finally, the three isolated nVarIBDV strains were inoculated into 3-week-old SPF chickens, and the bursa of the challenged chickens was collected on the 5th day after inoculation, and the supernatant of the ground tissue was collected as nVarIBDV seed virus.
[0103] The above three IBDV viruses were selected for further study. The VP2 genes of HB / 1208 / 2020 and XT / 1203 / 2021 are SEQ ID NO.5 and SEQ ID NO.6, respectively;
[0104] Next, the HA gene of CQ / 22 and the VP2 gene of WD / 22 were used as examples to construct recombinant viruses, and the remaining recombinant viruses can be prepared by referring to this method.
[0105] Part III Quantification of nVarIBDV and establishment of animal challenge model
[0106] Since nVarIBDV has limited replication ability in chicken embryos, SPF chickens were selected to quantify nVarIBDV virus. The harvested WD strain bursal grinding fluid was serially diluted 10 times, and 5 SPF chickens were inoculated with each dilution. The bursal weight ratio was calculated by counting the weight of the inoculated chickens and the bursal weight, and finally the bursal weight index (BBIX, BBIX = bursal weight ratio of chickens in the experimental group / average bursal weight ratio of chickens in the blank control group) was calculated. BBIX < 0.7 was considered as the onset of infection. After quantification, the WD virus content of this proliferation was 1×10 4 BID 50 .
[0107] In order to evaluate the immune protection effect of the vaccine, the nVarIBDV-infected SPF chicken animal model was constructed for vaccine evaluation.
[0108] WD / 0106 / 2022 and BC6 / 85 were selected as the challenge strains for the IBDV infected animal model, and the challenge dose was determined to be 30 BID based on the evaluation materials of the immune effect of IBDV vaccines in my country. 50 / feather, successfully established the IBDV infection model, compared with the blank control group chickens, the bursa of Fabricius of the infected chickens was significantly atrophied ( Figure 5A ), and the BBIX index of infected chickens is less than 0.7 ( Figure 5B ).
[0109] Part IV Construction and identification of HVT-H9-IBD recombinant virus
[0110] Using bacterial artificial chromosome (BAC) technology, an infectious clone HVT-BAC of turkey herpes virus (HVT) was constructed, and HVT-H9 expressing the HA gene of avian influenza virus was constructed using galk screening technology and CRISPR / Cas9 technology. Subsequently, in order to construct an HVT-H9-IBD virus expressing the H9N2 AIV HA gene and the infectious bursal disease virus VP2 gene, the galk screening technology was used, with the help of SW102 genetic engineering bacteria, to construct the HVT-BAC-H9 infectious clone, and the VP2 eukaryotic expression cassette was inserted into the HVT-BAC-H9 infectious clone in two steps. The construction method of the infectious clone HVT-BAC has been described in detail by the inventor in the patent CN109402071A previously applied for a recombinant turkey herpes virus expressing the H9 protein of the H9N2 subtype avian influenza virus, see paragraphs 109-113 for details, so this application will not be expanded.
[0111] Briefly, the galk screening technology was used in SW102 bacteria to insert the H9 eukaryotic expression cassette containing the CMV promoter and the bgH terminator into the HVT-BAC infectious clone to construct the HVT-BAC-H9 infectious clone; then the VP2 eukaryotic expression cassette containing the mCMV promoter and the SV40 terminator was inserted into the HVT-BAC-H9 infectious clone to construct the HVT-BAC-H9-VP2 infectious clone; further, the CRISPR / Cas9-induced homologous recombination technology was used to replace the BAC sequence with the donor gene when an exogenous donor gene consistent with HVT was provided, thereby obtaining the HVT-H9-IBD recombinant virus with only the HA and VP2 gene eukaryotic expression cassettes inserted. Since the recombinant virus HVT-H9-IBD does not contain GFP green fluorescent protein, HVT-H9-IBD can be successfully screened by screening plaques that do not contain green fluorescence.
[0112] 4.1 Construction of recombinant HVT-BAC-H9 infectious clone
[0113] In order to construct an HVT virus expressing the HA gene of the H9N2 subtype avian influenza virus, this example uses the galk galactokinase screening technology and, with the aid of the SW102 genetic engineering bacteria, inserts the HA eukaryotic expression cassette into the HVT-BAC infectious clone in two steps.
[0114] The specific steps are as follows:
[0115] In the first step, peGFP-galk was used as a template and amplified with primers homo-053galk-F / R (Table 1) containing a 50 bp homology arm. The PCR product was purified and electroporated into SW102 competent cells containing HVT-BAC for recombination and screening of SW102 bacteria containing HVT-BAC-053galk clones in galactose medium.
[0116] The SW102 genetically engineered bacteria and peGFP-galk in this step are described in the following literature: Warming S, Costantino N, Court DL, Jenkins NA, and Copeland N G. Simple and highly efficient BAC recombineering using galK selection. 2005; 33: e36-e36.
[0117] In the second step, the pcDNA-H9 plasmid was used as a template and the primers homo-053H9-F / R (Table 1) containing a 50 bp homology arm were used for amplification. The PCR product was purified and electroporated into the SW102 competent cell containing HVT-BAC-053galk. After recombination, it was screened in a basic medium containing 2-deoxy-galactose (DOG, content 2‰) to obtain the SW102 clone containing HVT-BAC-H9.
[0118] Schematic diagram of constructing HVT-BAC-H9 using the galk screening technology Fig. 6A , Figure 6B shown.
[0119] The specific operations are as follows:
[0120] 4.1.1HVT-BAC-053galk infectious clone preparation:
[0121] Step 1: Take 500 μl of SW102 bacterial solution containing HVT-BAC vector and add it to 10 ml LBCm+ complete medium for overnight screening and culture. The next day, in a 250 ml conical culture flask containing a barrier, take 5 ml of overnight culture solution and add it to 150 ml LBCm+ complete medium. Culture in a 32°C water bath shaker until the OD600 value reaches 0.55-0.6 to obtain culture medium.
[0122] Step 2: Then place the culture medium in a 42°C water bath shaker for heat shock induction for 15 minutes to obtain a bacterial solution.
[0123] Step 3: Cool the induced bacterial solution in an ice-water mixture, transfer it to two 50 ml centrifuge tubes, and centrifuge it at 5000 rpm and 4°C for 5 min. Prepare the electroporation competent cells according to conventional methods.
[0124] Step 4: Using peGFP-galk as a template, PCR amplification was performed using a primer pair consisting of homo-053galk-F (containing a 50 bp homology arm) and homo-053galk-R (containing a 50 bp homology arm) to obtain a DNA fragment of approximately 1296 bp, which was purified to obtain a homo-053galk-F / R PCR product.
[0125] Step 5: The purified homo-053galk-F / R PCR product was mixed with the electroporation competent cells and electroporated using a 0.1 cm electroporation cuvette with the following parameters: 25 μF, 1.75 kV, and 200 Ω.
[0126] Step 6: After electroporation, resuspend with 450 μl SOC, rejuvenate the bacteria in a shaker at 32°C for 1-2 hours, centrifuge at 10,000 rpm for 1 minute, wash the bacteria twice with 1×M9 saline, and spread on a basal medium plate containing galactose and culture for 3-4 days.
[0127] Step 7: Use MacConkey plates containing 2‰ galactose to screen and purify the SW102 bacteria containing the HVT-BAC-053galk infectious clone (similar methods can be found in CN109402071A, a recombinant turkey herpes virus expressing the H9 protein of the H9N2 subtype avian influenza virus, paragraphs 128-133 of the instruction manual).
[0128] 4.1.2 Preparation of HVT-BAC-H9 infectious clone:
[0129] First, the H9 open reading frame (ORF) was amplified using primers H9-F / R (Table 1), and then digested with KpnI and BamHI and ligated into pcDNA3.1+ to construct the H9 eukaryotic expression vector pcDNA-H9.
[0130] In order to obtain HVT-BAC-H9 infectious clones, the second step of galk screening was followed to perform electroporation and recombination. The specific steps are as follows:
[0131] Step 1: Add 500 μl of SW102 bacterial solution containing HVT-BAC-053galk to 10 ml of LBCm+ complete medium for overnight culture. The next day, take 5 ml of the overnight culture solution and add it to 150 ml of LBCm+ complete medium in a 50 ml conical culture flask containing a barrier. Culture at 32°C in a shaking water bath until the OD600 value reaches 0.5-0.6 to obtain the bacterial solution.
[0132] Step 2: Then transfer the bacterial solution to a 42°C water bath shaker for heat shock for 15 minutes for induction.
[0133] Step 3: Cool the induced bacterial solution in an ice-water mixture and transfer it to two 50 ml centrifuge tubes. Centrifuge at 5000 rpm and 4°C for 5 min. Prepare the electroporation competent cells according to conventional methods.
[0134] Step 4: Use pcDNA-H9 plasmid as template and homo 053H9-F / R primer pair for PCR amplification to obtain a DNA fragment of about 2834 bp, which is purified to obtain homo H9 F / R amplification product.
[0135] Step 5: After the purified homo H9 F / R amplification product is mixed with the electroporation competent medium, electroporation is performed in a 0.1 cm cuvette with the parameters of 25 μF, 1.75 KV, and 200 Ω.
[0136] Step 6: After electroporation, resuspend with 450 μl SOC, rejuvenate the bacteria in a shaker at 32°C for 1-2 hours, centrifuge at 10,000 rpm for 1 minute, wash twice with 1×M9 saline, apply to a basal medium plate containing deoxygalactose (DOG), and culture for 4 days. Finally, SW102 bacteria containing HVT-BAC-H9 were obtained.
[0137] Step 7: Extract the plasmid of SW102 bacteria containing the recombinant plasmid HVT-BAC-H9 to obtain the recombinant plasmid HVT-BAC-H9.
[0138] 4.2 Construction of recombinant HVT-BAC-H9-IBD infectious clone
[0139] In order to construct an HVT virus expressing the HA gene of the H9N2 subtype avian influenza virus and the VP2 gene of the infectious bursal disease virus, this example uses the galk galactokinase screening technology and the SW102 genetic engineering bacteria to insert the VP2 eukaryotic expression cassette into the HVT-BAC-H9-IBD infectious clone in two steps.
[0140] The specific steps are as follows:
[0141] In the first step, peGFP-galk was used as a template and amplified with primers homo-065galk-F / R (or homo-087galk-F / R) (Table 1) containing a 50 bp homology arm. The PCR product was purified and electroporated into the SW102 competent cell containing HVT-BAC for recombination and screening of SW102 bacteria containing HVT-BAC-H9-065galk (or HVT-BAC-H9-087galk) clones in galactose medium.
[0142] The SW102 genetically engineered bacteria and peGFP-galk in this step are described in the following literature: Warming S, Costantino N, Court DL, Jenkins NA, and Copeland N G. Simple and highly efficient BAC recombineering using galK selection. 2005; 33: e36-e36.
[0143] In the second step, pcDNA-H9 plasmid was used as a template and primers homo-065VP2-F / R (or homo-087VP2-F / R) (Table 1) containing a 50 bp homology arm were used for amplification. The PCR product was purified and electroporated into the SW102 competent cell containing HVT-BAC-H9-065galk (or HVT-BAC-H9-087galk). After recombination, it was screened in a basic medium containing 2-deoxy-galactose (DOG, content 2‰) to obtain SW102 clones containing HVT-BAC-H9-065IBD (or HVT-BAC-H9-087IBD).
[0144] Schematic diagram of constructing HVT-BAC-H9 using galK screening technology Fig. 6A , Figure 6B shown.
[0145] The specific operations are as follows:
[0146] 4.2.1 Preparation of HVT-BAC-H9-065galk (or HVT-BAC-H9-087galk) infectious clone:
[0147] Step 1: Take 500 μl of SW102 bacterial solution containing HVT-BAC-H9 vector and add it to 10 ml LBCm+ complete medium for overnight screening and culture. The next day, in a 250 ml conical culture flask containing a barrier, take 5 ml of the overnight culture solution and add it to 150 ml LBCm+ complete medium. Culture in a 32°C water bath shaker until the OD600 value reaches 0.55-0.6 to obtain the culture medium.
[0148] Step 2: Then place the culture medium in a 42°C water bath shaker for heat shock induction for 15 minutes to obtain a bacterial solution.
[0149] Step 3: Cool the induced bacterial solution in an ice-water mixture, transfer it to two 50 ml centrifuge tubes, and centrifuge it at 5000 rpm and 4°C for 5 min. Prepare the electroporation competent cells according to conventional methods.
[0150] Step 4: Using peGFP-galk as a template, PCR amplification was performed using a primer pair consisting of homo-065galk-F (or homo-087galk-F) (containing a 50 bp homology arm) and homo-065galk-R (or homo-087galk-R) (containing a 50 bp homology arm) to obtain a DNA fragment of approximately 1296 bp, which was purified to obtain a homo-065galk-F / R (or homo-087galk-F / R) PCR product.
[0151] Step 5: Mix the purified homo-065galk-F / R (or homo-087galk-F / R) PCR product with the electroporation competent cell and perform electroporation using a 0.1 cm electroporation cup with parameters of 25 μF, 1.75 kV, and 200 Ω.
[0152] Step 6: After electroporation, resuspend with 450 μl SOC, rejuvenate the bacteria in a shaker at 32°C for 1-2 hours, centrifuge at 10,000 rpm for 1 minute, wash the bacteria twice with 1×M9 saline, and spread on a basal medium plate containing galactose and culture for 3-4 days.
[0153] Step 7: Use MacConkey plates containing 2‰ galactose to screen and purify the SW102 bacteria containing the infectious clone of HVT-BAC-H9-065galk (or HVT-BAC-H9-087galk) (similar methods can refer to CN109402071A, a recombinant turkey herpes virus expressing the H9 protein of the H9N2 subtype avian influenza virus, paragraphs 128-133 of the instruction manual).
[0154] 4.2.2 Preparation of HVT-BAC-H9-065IBD (or HVT-BAC-H9-087IBD) infectious clone:
[0155] First, primers VP2-F / R (Table 1) were used to fuse the VP2 gene with the mCMV promoter and SV40 terminator of the pDC315 vector using overlapping PCR to prepare a VP2 eukaryotic expression cassette, which was then ligated into a T vector to construct pT-VP2exp.
[0156] In order to obtain the infectious clone of HVT-BAC-H9-065IBD (or HVT-BAC-H9-087IBD), the second step of galk screening was followed to perform electroporation and recombination. The specific steps are as follows:
[0157] Step 1: Add 500 μl of SW102 bacterial solution containing HVT-BAC-H9-065galk (or HVT-BAC-H9-087galk) to 10 ml of LBCm+ complete medium and culture overnight. The next day, take 5 ml of the overnight culture solution and add it to 150 ml of LBCm+ complete medium in a 50 ml conical culture flask containing a barrier. Culture at 32°C in a shaking water bath until the OD600 value reaches 0.5-0.6 to obtain the bacterial solution.
[0158] Step 2: Then transfer the bacterial solution to a 42°C water bath shaker for heat shock for 15 minutes for induction.
[0159] Step 3: Cool the induced bacterial solution in an ice-water mixture and transfer it to two 50 ml centrifuge tubes. Centrifuge at 5000 rpm and 4°C for 5 min. Prepare the electroporation competent cells according to conventional methods.
[0160] Step 4: Use pT-VP2 exp plasmid as template and homo-065VP2-F / R (or homo-087VP2-F / R) primer pair for PCR amplification to obtain a DNA fragment of about 2224 (or 2110) bp, purify it, and obtain the homo-065VP2-F / R (or homo-087VP2-F / R) amplification product.
[0161] Step 5: After the purified homo-065VP2-F / R (or homo-087VP2-F / R) amplification product is mixed with the electroporation competent medium, electroporation is performed in a 0.1 cm beating cup with the parameters of 25 μF, 1.75 KV, and 200 Ω.
[0162] Step 6: After electroporation, resuspend with 450 μl SOC, rejuvenate the bacteria in a shaker at 32°C for 1-2 hours, centrifuge at 10,000 rpm for 1 minute, wash twice with 1×M9 saline, apply to a basal medium plate containing deoxygalactose (DOG), and culture for 4 days. Finally, SW102 bacteria containing HVT-BAC-H9-065IBD (or HVT-BAC-H9-087IBD) were obtained.
[0163] Step 7: Extract the plasmid of SW102 bacteria containing the recombinant plasmid HVT-BAC-H9-065IBD (or HVT-BAC-H9-087IBD) to obtain the recombinant plasmid HVT-BAC-H9-065IBD (or HVT-BAC-H9-087IBD).
[0164] 4.3 Preparation of recombinant live vector vaccine HVT-H9-065IBD (or HVT-H9-087IBD)
[0165] In order to delete the BAC sequence, this example uses CRISPR / Cas9 technology to first design and synthesize sgRNA primers (sgRNA-F / R, Table 1), and link sgRNA to pX458 vector to construct CRISPR plasmid pX458-sgRNA containing sgRNA. The operating steps have been described in detail in the patent CN109402071A previously applied by the inventors in a recombinant turkey herpes virus expressing H9 protein of H9N2 subtype avian influenza virus, see paragraphs 138-145 of the specification for details.
[0166] In order to completely delete the BAC sequence and make it completely consistent with the parent virus, this example provides a donor gene (donor-F / R, Table 1) that is consistent with the HVT parent virus sequence, and uses CRISPR / Cas9 to cut the DNA double-strand breaks to induce homologous recombination repair, so that the donor gene replaces the BAC sequence, thereby deleting the BAC sequence and obtaining the HVT-H9-065IBD (or HVT-H9-087IBD) virus ( Fig. 7A , Figure 7B ).
[0167] The sequence information of the donor gene is: 139462nt-141036nt of the genomic DNA of HVT (FC-126 strain), and the specific preparation process is: using the genomic DNA of HVT as a template, using the primer pair consisting of donor-F and donor-R to perform PCR amplification, and the obtained DNA fragment (139462nt-141036nt of the genomic DNA of HVT (FC-126 strain));
[0168] The specific operation is to co-transfect the constructed pX458-sgRNA, HVT-BAC-H9-065IBD (or HVT-BAC-H9-087IBD) plasmid and donor (using the genomic DNA of HVT as a template, and using the primer pair composed of donor-F and donor-R for PCR amplification, the obtained DNA fragment (139462nt-141036nt of the genomic DNA of HVT)) into 6-well CEF cells grown to 90% density in advance, and then subculture into new CEF cells for screening 6-7 days after transfection, and screen the plaques without green fluorescence to obtain HVT-H9-065IBD (or HVT-H9-087IBD) virus.
[0169] Part V Identification of HVT-H9-IBD recombinant virus plaque morphology
[0170] CEF cells were infected with HVT-H9-065IBD, HVT-H9-087IBD and HVT parental viruses, respectively, and plaque morphology was observed using an inverted microscope 5 days after infection ( Figure 8 The results showed that the plaque morphology and size of the recombinant viruses HVT-H9-065IBD and HVT-H9-087IBD were similar to those of the parent virus HVT.
[0171] Part VI: Identification of the Replication Capacity of Recombinant Viruses
[0172] CEF cells were prepared and plated in 6-well cell plates. The next day, each well of CEF cells was inoculated with 100 PFU of HVT-H9-065IBD, HVT-H9-087IBD, and HVT parental viruses;
[0173] Three wells were collected at 24, 48, 72, 96, and 120 h after inoculation, and the virus was quantified using the 2-fold serial dilution method, and the growth curve was finally drawn.
[0174] The results showed that there was no difference in the in vitro growth and replication ability of the recombinant viruses HVT-H9-065IBD and HVT-H9-087IBD and the parent virus HVT ( Fig. 9 ), HVT-H9-087IBD is slightly better than HVT-H9-065IBD.
[0175] Part VII Detection of the expression of exogenous genes HA and VP2 in HVT-H9-IBD
[0176] 7.1 HA gene expression detection
[0177] 7.1.1 HA gene expression IFA detection
[0178] CEF cells were prepared and inoculated with HVT-H9-IBD virus. After 72 hours of infection, the prepared HA protein mouse monoclonal antibody was used as the primary antibody, and FITC-labeled anti-mouse secondary antibody was used for IFA staining.
[0179] CEF cells were infected with HVT-H9-IBD for 72 h and normal CEF cells were infected with HVT-H9-IBD for 72 h. Fig.10 ), HA mouse monoclonal antibody was used as the primary antibody, FITC-labeled goat anti-mouse fluorescent secondary antibody was used for IFA staining, and the samples were observed under a fluorescence microscope at a magnification of 100×.
[0180] The results showed that the HVT-H9-IBD recombinant virus could correctly express the HA gene.
[0181] 7.1.2 HA gene expression Western-blot detection
[0182] CEF cells were infected with HVT-H9-IBD, CQ / 22 and HVT viruses, respectively, and proteins were collected and Western-blot staining was performed using mouse HA monoclonal antibody as the primary antibody.
[0183] After 72 h of HVT-H9-IBD virus infection, proteins in the 6-well plate were collected and Western-blot identification was performed using homemade mouse monoclonal antibodies as primary antibodies ( Fig.11A , Fig. 11C ), the results showed that the HA band of about 62.9KD could be detected by HVT-H9-IBD and CQ / 22, while no HA protein band was detected by HVT virus.
[0184] 7.2 VP2 gene expression detection
[0185] 7.2.1 VP2 gene expression IFA detection
[0186] CEF cells were prepared and inoculated with HVT-H9-087IBD virus. After 72 hours of infection, the prepared VP2 protein mouse polyclonal antibody was used as the primary antibody, and FITC-labeled anti-mouse secondary antibody was used for IFA staining.
[0187] CEF cells were infected with HVT-H9-IBD for 72 h and normal CEF cells were infected with HVT-H9-IBD for 72 h. Fig.10 ), VP2 mouse polyclonal antibody was used as the primary antibody, FITC-labeled goat anti-mouse fluorescent secondary antibody was used for IFA staining, and the cells were observed under a fluorescence microscope at a magnification of 100×.
[0188] The results showed that the HVT-H9-IBD recombinant virus could correctly express the VP2 gene.
[0189] 7.2.2 VP2 gene expression Western-blot detection
[0190] CEF cells were infected with HVT-H9-IBD, WD / 22 and HVT viruses, respectively, and proteins were collected and Western-blot staining was performed using mouse VP2 polyclonal antibody as the primary antibody.
[0191] After 72 h of HVT-H9-IBD virus infection, proteins in the 6-well plate were collected and Western-blot identification was performed using homemade mouse polyclonal antibodies as primary antibodies ( Fig. 11B , Fig.11D ), the results showed that the VP2 band of about 48.66KD could be detected by HVT-H9-IBD and WD / 22, while the VP2 protein band was not detected by HVT virus.
[0192] Part 8. In vitro genetic stability test of HVT-H9-IBD
[0193] In order to detect the genetic stability of HVT-H9-IBD virus, in this example, 100 PFU HVT-H9-IBD virus was used to infect CEF cells, and the cell supernatant was discarded 1 hour after infection. The cells were washed twice with PBS, and the DMEM cell maintenance medium containing 1% FBS was replaced. After culturing for 3-4 days, the cells were digested, and a certain amount of virus was inoculated on new CEF cells. This operation was repeated for 20 generations, and the virus was collected every 5 generations. The collected viral DNA was identified by PCR using H9-F / R and VP2-F / R primers (Table 1) ( Fig. 12A , Fig. 12B , Fig. 12C , Fig.12D ) and Western-blot was used to detect the expression of viral HA and VP2 proteins ( Fig.13A , Fig. 13B , Fig. 13C , Fig.13D ).
[0194] The results showed that the HA and VP2 genes of HVT-H9-IBD could be stably inherited.
[0195] Part 9 Evaluation of immune protection of HVT-H9-IBD recombinant virus
[0196] 9.1H9N2 partial immune protection evaluation
[0197] 9.1.1 Detection of HI antibody levels
[0198] One-day-old SPF chickens were immunized with HVT-H9, HVT-H9-065IBD, and HVT-H9-087IBD, respectively, at 2000 PFU / bird. A negative control of HVT immunization was also set up. Blood was collected on days 14, 21, 28, and 35 after immunization to prepare serum, and the HI antibody level induced by immunization was detected by hemagglutination inhibition test ( Fig.14 ).
[0199] Preparation of HVT-H9 HVT-H9 was prepared by referring to the method of CN109402071A. The sequence of the HA gene of HVT-H9 is the same as the HA gene sequence used in the present invention.
[0200] The results showed that HVT-H9 and HVT-H9-087IBD produced similar levels of HI antibodies, while HVT-H9-065IBD produced relatively low levels of HI antibodies.
[0201] 9.1.2 Evaluation of protection against challenge with homologous H9N2 avian influenza virus
[0202] On day 28 after immunization, 10 chickens immunized with HVT-H9, HVT-H9-065IBD, and HVT-H9-087IBD were taken out and injected intravenously with 2×10 6 EID 50 / 0.2mL dose CQ / 22, and HVT vector virus was set as the virus control. On the 5th day after the virus attack, the laryngeal and cloacal swabs of each chicken were collected, and the laryngeal and cloacal swabs of the same chicken were mixed into one sample. Each sample was inoculated with 5 10-day-old SPF chicken embryos through the allantoic cavity, 0.2mL per embryo, incubated at 37°C and observed for 96 hours. The hemagglutination (HA) titer of the chicken embryo fluid was measured for both live and dead embryos. As long as the HA titer of the embryo fluid of one of the five chicken embryos inoculated with each mixed swab sample is not less than 1:16, it can be judged as positive for virus isolation. For samples with negative virus isolation, they are blindly transmitted once and then judged. If both isolations are negative, it is judged as protection, and if any isolation is positive, it is judged as non-protective ( Fig.15 ).
[0203] The results showed that both HVT-H9 and HVT-H9-087IBD could protect against homologous virus challenge, with the protection rate reaching 100% on the 5th day after challenge. HVT-H9-065IBD could partially protect against homologous virus challenge, with the protection rate reaching 70% on the 5th day after challenge. The protection rate of the HVT challenge control group was 0.
[0204] 9.2 Evaluation of IBD Partial Immune Protection
[0205] 9.2.1 Evaluation of protection against infectious bursal disease virus challenge
[0206] HVT-065IBD, HVT-087IBD, HVT-H9-065IBD, and HVT-H9-087IBD were used to immunize 1-day-old SPF chickens with 2000 PFU / bird, and 1-day-old SPF chickens with 2000 PFU / bird. 28 days after immunization, 30 BIDs were challenged with the virus 50 The dose was WD / 0106 / 2022, and the HVT vector virus was set as the challenge control and blank control.
[0207] The chickens were weighed 7 days after the challenge, and the bursa of Fabricius was dissected and weighed to calculate the bursa index (BBIX) (bursa weight ratio = (bursa weight / body weight) × 1000; BBIX = bursa weight ratio of chickens in the experimental group / average bursa weight ratio of chickens in the blank control group). Based on BBIX>0.7 as the protection threshold, Fig.16A The BBIX of HVT-IBD and HVT-H9-087IBD after immunization was significantly greater than 0.7, and the BBIX of HVT-H9-065IBD after immunization was greater than 0.7, while the BBIX of the control group was less than 0.7. Fig. 16B It can be seen that the immune protection rate of HVT-IBD and HVT-H9-087IBD reached 100%, the protection rate of HVT-H9-065IBD against toxic substances reached 90%, while the protection rate of the control group against toxic substances was 0%.
[0208] 9.2.2 Evaluation of protection against challenge with virulent IBDV virus strains
[0209] The VP2 genes of HB / 1208 / 2020 and XT / 1203 / 2021 were selected as replacement fragments. Using the same construction strategy, galk screening technology and CRISPR / Cas9 technology, the HA eukaryotic expression cassette containing the CMV promoter and bgH terminator was inserted between 087 and 088 of the HVT-BAC-H9 infectious clone to construct HVT-H9-087IBD / HB and HVT-H9-087IBD / XT, respectively.
[0210] HVT-H9-087IBD, HVT-H9-087IBD / HB and HVT-H9-087IBD / XT were immunized into 1-day-old SPF chickens, 2000 PFU / feather. 28 days after immunization, 30 BID50 doses of BC6 / 85 test strong strain were challenged, and HVT vector virus was set as challenge control and blank control.
[0211] The chickens were weighed 7 days after the challenge, and the bursa of Fabricius was dissected and weighed to calculate the bursa index (BBIX) (bursa weight ratio = (bursa weight / body weight) × 1000; BBIX = bursa weight ratio of chickens in the experimental group / average bursa weight ratio of chickens in the blank control group). Based on BBIX>0.7 as the protection threshold, Fig.17A The BBIX of the chickens challenged with HVT-H9-087IBD, HVT-H9-087IBD / HB and HVT-H9-087IBD / XT was greater than 0.7, while that of the control group was less than 0.7. Fig. 17B It can be seen that the immune protection rate of HVT-H9-087IBD reached 90%, the protection rates of HVT-H9-087IBD / HB and HVT-H9-065IBD / XT reached 80% and 70%, respectively, while the protection rate of the challenge control group was 0%.
[0212] Part 10 Results Analysis
[0213] 1. The above experiments show that the HA gene and VP2 gene of the present invention combined with HVT can prepare a recombinant virus that provides good immune protection against nVarIBDV and H9N2 subtype avian influenza.
[0214] 2. The hypervariable region of the VP2 gene of the present invention has 12 amino acid mutations, and its immune protection effect is better than that of the XT strain and HB strain isolated at the same time;
[0215] At the same time: In the prior art, the existing HVT-IBD vaccines are all targeted at strong strains, and there are no HVT-IBD recombinant vaccines targeting new variants. Previous literature shows that the HVT-IBD recombinant vaccines targeting strong strains are not effective in protecting against the current new variants;
[0216] The new variant of IBDV is an early infection in clinical broilers and is an important disease that affects the production performance of broilers. The HVT-H9-IBD of the present invention is the most effective vaccine for broilers.
[0217] The HA gene of the present invention is a typical G3 antigen group H9N2 subtype avian influenza virus, which belongs to the antigen subgroup currently popular on the market. By transferring the HA gene into turkey herpes virus, it is verified that it has extremely strong protective power.
[0218] 3. The present invention surprisingly found that even if the same gene is inserted into different non-coding regions of HVT, the effects produced are completely different. For example, the gene inserted into the 065 site of the UL region not only affects the immune protection effect of the VP2 gene, but also affects the immune protection effect of the HA gene.
[0219] 4. In the present invention, we collected several popular H9N2 subtype avian influenza viruses and nVarIBDV recently, and used their HA genes and VP2 genes to construct recombinant viruses. We found that there were obvious differences in immune protection. The possible reasons for this phenomenon are: 1. There is a certain degree of difficulty and contingency in selecting a suitable target gene; 2. The protection effect is closely related to the insertion site.
[0220] In summary, the replication ability of the recombinant virus obtained in the present invention is consistent with that of the parent virus, and can provide good immune protection for H9N2 subtype avian influenza virus and new variants of IBDV, meeting the requirements of vaccine candidate strains.
Claims
1. A recombinant turkey herpes virus HVT-H9-IBD expressing two exogenous genes, characterized in that: Inserting target gene 1 and target gene 2 between HVT053 site and HVT054 site and between HVT065 site and HVT066 site of UL region of turkey herpes virus, respectively; or, inserting the target gene 1 and the target gene 2 between the HVT053 site and the HVT054 site and between the HVT087 site and the HVT088 site of the UL region of turkey herpes virus, respectively; The target gene 1 is the HA gene with a promoter and a terminator, and the target gene 2 is the VP2 gene with a promoter and a terminator, and recombinant virus 1 and recombinant virus 2 are obtained respectively.
2. The recombinant turkey herpes virus HVT-H9-IBD according to claim 1, characterized in that The nucleotide sequence of the HA gene is shown in SEQ ID NO.1; the nucleotide sequence of the VP2 gene is shown in SEQ ID NO.
2.
3. The recombinant turkey herpes virus HVT-H9-IBD according to claim 1, characterized in that The promoter of the inserted HA gene is a CMV promoter, and the terminator is a bgH terminator; the promoter of the inserted VP2 gene is an mCMV promoter, and the terminator is an SV40 terminator.
4. Use of the recombinant turkey herpes virus HVT-H9-IBD as claimed in claim 1 to prepare a vaccine for preventing infection by H9N2 subtype avian influenza and new variants of infectious bursal disease.
5. A vaccine, characterized in that Contains the recombinant turkey herpes virus HVT-H9-IBD as described in any one of claims 1 to 3.
Citation Information
Patent Citations
Construction method and application of HVT co-expressing NDV HN and IBDV VP2 genes
CN107099513A
Recombinant turkey herpesvirus expressing H9N2 subtype avian influenza virus (AIV) H9 proteins
CN109402071A
Fused gene, recombinant expression vector, antigen, preparation method and application
CN110128545A
VP2 protein subunit vaccine of infectious bursal disease virus variant as well as preparation method and application of VP2 protein subunit vaccine
CN117482220A
Construction method of recombinant turkey herpesvirus rHVT-HA-VP2
CN117551699A
Cited By
Recombinant turkey herpesvirus rHVT-F-HA-VP2 as well as construction method and application thereof
CN119955852A
Influenza HA protein recombinant herpesvirus turkey strain and application thereof
CN121294370A
Construction and application of recombinant herpesvirus turkey for co-expressing HA gene and F gene
CN121653080A
